Connecting Research and Experts with Journalists

• share
• favorite_border

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.

• share
• favorite_border

Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

Relaxor ferroelectrics have greatly enhanced electrical and mechanical properties that originate in the materials’ domain structure. Knowing how quickly these materials’ properties can change is critical to understanding them. However, scientists have not been able to measure how fast these materials can respond. This study measured this reaction speed using ultrafast electron diffraction at the atomic level to obtain snapshots of the evolving domain structure.

• share
• favorite_border

In a new study published October 25th in the Journal of the American Medical Association, Yale School of Medicine researchers set out to test whether rapidly delivered, personalized care recommendations from a dedicated "kidney action team" could improve outcomes for hospitalized patients with acute kidney injury (AKI).

• share
• favorite_border

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

• share
• favorite_border

A new study found that higher levels of stereotypical male gender expression were associated with a decrease in reported diagnoses and treatment for cardiovascular disease risk factors.